The level of AGEs can predict response to intravitreal anti-VEGF therapy in DME
Verkorte titel
Health condition
diabetic retinopathy (DR)
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
treatment success
Achtergrond van het onderzoek
The aim of this study is to investigate the relationship between advanced glycation end products (AGEs) and treatment
responsiveness to anti-vascular endothelial growth factor (anti-VEGF) in diabetic macular edema (DME) patients.
Doel van het onderzoek
The level of AGEs can predict response to intravitreal anti-VEGF therapy in DME
Onderzoeksopzet
baseline, 1 year
Onderzoeksproduct en/of interventie
none
Publiek
Wetenschappelijk
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Patients diagnosed with DME who started inravitreal anti-VEGF therapy less than 1 yr ago
· Age: >18 years.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Dark coloured skin (Fitzpatrick type V or VI).
· Skin abnormalities on both arms that will impair the reliability of the autofluorescence
measurement.
· Local or general active infection or inflammatory disease.
· Known renal disease, current dialysis treatment, or a history of renal transplantation.
· Patients with high myopia (>6 diopters), glaucoma, combined retinal disease, media
opacities interfering with OCT imaging, vitreomacular traction on SD-OCT and those
whose SD-OCT images were of poor quality, intraocular surgery within 12 weeks prior
to the first injection
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Toelichting
In dit register bekende (historische) registraties
Geen registraties gevonden
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL8431 |
| Ander register | METc UMCG : METc2019/600 |